Nov 24, 2021 | 2021, Press Releases, Scientific
More datailsNov 12, 2021 | 2021, Press Releases, Scientific
Philogen to hold a Webinar at 11 am EST / 4 pm GMT / 5 pm CET on Friday 12th November 2021, Click here to view Press Release 12-11-2021Nov 4, 2021 | 2021, Events, Scientific
Dario Neri, co-founder, CEO and CSO, is giving a presentation to address the question on how to achieve the therapeutic dose at the tumor site with cytokine-based targeted products. Roberto De Luca, Head of Antibody Therapeutics at Philogen, is also giving a...Nov 3, 2021 | 2021, Events, Scientific
Dario Neri, co-founder, CEO and CSO, is giving a presentation focused on Tripokin, a novel fusion protein capable of an exceptionally selective uptake at the tumor site. The product contains two highly synergistic cytokine moieties (interleukin-2 and tumor necrosis...Oct 15, 2021 | 2021, Press Releases, Scientific
Philogen announces that Philochem’s European Patent 3083957 relating to important features of proprietary DNA-encoded chemical libraries (“ESAC 2+1” technology) was upheld after Oral Proceedings in front of the Opposition Division at the European Patent Office. Read...Oct 13, 2021 | 2021, Press Releases, Scientific
Philogen S.p.A. announces an update on the worldwide license agreement with Pfizer to develop Dekavil, a novel investigational therapy for the treatment of autoimmune diseases. Read more
Recent Comments